{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:49:30Z","timestamp":1769003370716,"version":"3.49.0"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>A Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) led to a pandemic outbreak in 2019. COVID-19\u2019s course and its treatment in immunocompromised patients are uncertain. Furthermore, there is a possibility of protracted SARS-CoV-2 infection and the need for repeated antiviral treatment. Monoclonal antibodies against CD20, which are used, among other things, in the therapy of chronic lymphocytic leukaemia and follicular lymphoma, can induct immunosuppression. We present a case report of a patient with follicular lymphoma, treated with obinutuzumab, who was diagnosed with prolonged, ongoing SARS-CoV-2 infection and related organizing pneumonia. The recognition and the treatment were challenging which makes this case noteworthy. Antiviral therapy with several medications was administrated to our patient and their temporary, positive effect was observed. Moreover, high-dose intravenous immunoglobulin was applied, because slowly decreasing IgM and IgG levels were observed. The patient also received standard treatment of organizing pneumonia. We believe that such a complex approach can create an opportunity for recovery. Physicians should be conscious of the course and treatment possibilities facing similar cases.<\/jats:p>","DOI":"10.3390\/v15030693","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T03:29:05Z","timestamp":1678246145000},"page":"693","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab\u2014Challenging Recognition and Treatment"],"prefix":"10.3390","volume":"15","author":[{"given":"E.","family":"\u0141y\u017cwa","sequence":"first","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9311-9753","authenticated-orcid":false,"given":"M.","family":"Sobiecka","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4648-2864","authenticated-orcid":false,"given":"K.","family":"Lewandowska","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Siemion-Szcze\u015bniak","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bara\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Klatt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Langfort","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Szturmowicz","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Tomkowski","sequence":"additional","affiliation":[{"name":"1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: Obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient","volume":"223","author":"Baang","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ertesv\u00e5g, N.U., Sakkestad, S.T., Zhou, F., Hoff, I., Kristiansen, T., Jonassen, T.M., Folles\u00f8, E., Brokstad, K.A., Dyrhovden, R., and Mohn, K.G.-I. (2022). Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment. Viruses, 14.","DOI":"10.3390\/v14081757"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3389\/fonc.2020.01578","article-title":"Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab","volume":"10","author":"Kos","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000521121","article-title":"Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma","volume":"145","author":"Arribalzaga","year":"2022","journal-title":"Acta Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2169\/internalmedicine.9136-21","article-title":"Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma","volume":"61","author":"Ueda","year":"2022","journal-title":"Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e01611","DOI":"10.1016\/j.idcr.2022.e01611","article-title":"Detection of viable SARS-CoV-2 in deep respiratory specimens despite negative nasopharyngeal SARS-CoV-2 RT-PCR: Occult COVID-19 as an unsuspected cause of pulmonary infiltrates in immunocompromised patients","volume":"30","author":"Wee","year":"2022","journal-title":"IDCases"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/j.clml.2021.07.004","article-title":"Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient with Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections","volume":"21","author":"Yasuda","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","first-page":"8712424","article-title":"Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review","volume":"2022","author":"Burgener","year":"2022","journal-title":"Case Rep. Infect. Dis."},{"key":"ref_11","first-page":"003502","article-title":"A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature","volume":"9","author":"Peer","year":"2022","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.2147\/IDR.S393198","article-title":"Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy","volume":"15","author":"Seki","year":"2022","journal-title":"IDR"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e01099","DOI":"10.1002\/rcr2.1099","article-title":"A case of prolonged COVID-19 treated with tixagevimab\/cilgavimab","volume":"11","author":"Shimizu","year":"2023","journal-title":"Respirol. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.21873\/invivo.13100","article-title":"Prolonged SARS-CoV-2 Infection with Common Features in Two Patients Receiving Anti-CD20 Therapy","volume":"37","author":"Papanikolopoulou","year":"2023","journal-title":"In Vivo"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bjh.18315","article-title":"Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19","volume":"198","author":"Shafat","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"763412","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1097\/HS9.0000000000000603","article-title":"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma","volume":"5","author":"Gaitzsch","year":"2021","journal-title":"Hemasphere"},{"key":"ref_19","unstructured":"(2022, December 15). WHO Recommendation. Available online: https:\/\/app.magicapp.org\/#\/guideline\/nBkO1E\/section\/nJB6MR."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20420986211042516","DOI":"10.1177\/20420986211042517","article-title":"The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: An updated systematic review and meta-analysis","volume":"12","author":"Santenna","year":"2021","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/IDR.S396271","article-title":"Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti\u2013SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms","volume":"16","author":"Onishi","year":"2023","journal-title":"IDR"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/693\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:49:50Z","timestamp":1760122190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/3\/693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["v15030693"],"URL":"https:\/\/doi.org\/10.3390\/v15030693","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}